Expanding treatment options in mHSPC, real world differentiation and clinical outcomes

This project is intended for HCPs and has been supported by Bayer and fully created by EMJ.

Join leading prostate cancer experts, Kim Chi, Nick James, and Bertrand Tombal at ESMO 2025 in Berlin to discuss the latest developments in metastatic hormone sensitive prostate cancer (mHSPC) diagnosis and treatment. With mHSPC patients living longer how can patients with multiple morbidities be treated for all their health needs while minimising the risk of side effects?

Explore topics including:

• The global rise of mHSPC rates and potential approaches to earlier diagnosis
• Do patients really need to be treated for their whole life?
• The role of AI in diagnosis and management of patients
• The role for multidisciplinary teams to manage mHSPC patients with multiple morbidities
• The potential for personalised treatment strategies for mHSPC in the future

1. Moderator and Science Communicator
2. Université Catholique de Louvain (UCL), Cliniques Universitaires Saint-Luc, Brussels, Belgium
3. BC Cancer – Vancouver Centre, Vancouver Prostate Centre, and Faculty of Medicine, University of British Columbia, Vancouver, Canada
4. Institute of Cancer Research and The Royal Marsden NHS Foundation, London, UK